Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.

Anne Marie BarretteHalle RonkTanvi JoshiZarmeen MussaMeenakshi MehrotraAlexandros BourasGerman NudelmanJoe G Jesu RajDominique BozecWilliam LamJane HouldsworthRaymund YongElena ZaslavskyConstantinos G HadjipanayisMarc R BirtwistleNadejda M Tsankova

Published in: Neuro-oncology (2021)

We demonstrate combined anti-invasive and anti-proliferative efficacy for Verteporfin with survival benefit in preclinical GBM models, indicating potential therapeutic value of this already FDA-approved drug if repurposed for glioblastoma patients.

Keyphrases

end stage renal disease
newly diagnosed
cell therapy
prognostic factors
free survival
stem cells
emergency department
mesenchymal stem cells
bone marrow
patient reported
adverse drug